Drugs / CARTemis-1
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT05982275 | Dec 2024 → Dec 2029 expected | disease related to hematopoietic stem cell transplant, plasma cell myeloma | Andalusian Public Foundation for Health Research in Seville | Not yet recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CARTemis-1 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05982275 ↗ |
| Route | Intravenous | “self-administered intravenously” NCT05982275 ↗ |